Valirx Plc · LSE:VAL
Valirx — Shareholder Meeting (June 2022)
28 slides from Valirx's shareholder meeting presentation, Jun 30, 2022
Slide 1: AGM Presentation
AGM Presentation 30 June 2022 ValiRx @valirxplc www.valirx.com info@valirx.com
Slide 2: Disclaimer
Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the ‘Presentation’) have not been approved by an authorised person withi
Slide 3: ValiRx at a glance
ValiRx at a glance Net cash £1.2m 2 therapies Focus on oncology (H1/21) – significantly undergoing out- and women’s health reduced cash burn licensing 3 preclinical assets under evaluation – tCRO buy-and-build Collaboration with potential out-licensing strategy implemented external partners to candi
Slide 4: Team – a deep understanding of the sector
Team – a deep understanding of the sector Core Strategy Team Dr Suzanne Dilly Dr Kevin Cox Mark Treharne Chief Executive Officer Non-executive Chairman Corporate Development Manager Entrepreneur >25 years in Life Science Innovator network Pharmaceutical scientist leadership Investor Relations Transl
Slide 5: Pharmaceutical Development is flawed
Pharmaceutical Development is flawed Fundamental Issues in drug development innovation productivity access Failure to translate academic Failure in clinical trials due to Failure to recognise the research due to lack of poorly understood pre-clinical needs of women in drug expertise data development
Slide 6: Getting the preclinical stage right adds billions to the value of drugs
Getting the preclinical stage right adds billions to the value of drugs AI-driven virtual drug discovery Universities Biotech platform (in-house) Patent filed Mid-size Biotech/SPVs Big Pharma/Specialty Pharma Patent life (years) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Early Discovery Stag
Slide 7: ValiRx seeks to occupy a distinctive position
ValiRx seeks to occupy a distinctive position Opportunity to consolidate market and acquire new capabilities Small, niche innovative service companies Specialism Profitable standard lab capability service companies Size 7 Connected Innovation
Slide 8: 5 Year Plan
5 Year Plan Within 5 years, we believe we can: Create a revenue generating, profitable Translational Contract Research Organisation Acquire at least four, revenue-generating contract research organisations to integrate into our tCRO Target revenues of >£10m Out-license our legacy pipeline assets (Va
Slide 9: Summary – increasing value to shareholders
Summary – increasing value to shareholders ValiRx has the opportunity to create a top class tCRO, specialising in women’s health and oncology by: Expanding capabilities via M&A Employing the power of Generating deep biological consolidation of a fragmented advanced data generation, bio- understandin
Slide 10: Contacts
Contacts • Suzanne Dilly – Chief Executive Officer - Suzanne.dilly@valirx.com • Kevin Cox – Non-Executive Chairman - Kevin.cox@valirx.com • Mark Treharne – Corporate Development Manager - Mark.Treharne@valirx.com Valirx PLC (AIM:VAL) Eliot Park Innovation Centre, 4 Barling Way, Nuneaton, CV10 7RH 10
Slide 11: AGM Q&A
AGM Q&A ValiRx @valirxplc www.valirx.com info@valirx.com
Slide 12: Questions received in advance
Questions received in advance • AGM resolutions • New strategy • General Queries • Legacy Assets and licenses • VAL201 • VAL301 • VAL401 • BC201 • New Assets 12 Connected Innovation
Slide 13: AGM Resolutions
AGM Resolutions • Shareholders accept the need for a placing however rather than issue 40m shares now, half commercial half PI would you consider doing this in two smaller tranches? With the second deferred until market conditions improve or is this not possible? - Resolutions 4 and 6 refer to the s
Slide 14: New Strategy
New Strategy • You’ve made numerous references to acquiring a lab. Have you a lab in mind? What is the expected outlay for this lab? Will it be funded by debt, or the equity raise or a mixture? What will the ownership structure be, will it be 100% wholly owned by Valirx? - Our preference is that any
Slide 15: General Queries (1)
General Queries (1) • You are building a Biotech at the forefront of Women’s Oncology yet only have one female on the board. Are you going to do anything to redress the balance? • Kevin Alexander has resigned do you have a replacement NED are you looking for one? • Would you consider adding at least
Slide 16: General Queries (2)
General Queries (2) • Would you consider appointing Adam Hargreaves to the Board? - A position on the Board of a listed company, even as a non-executive director, entails responsibilities and significant regular time commitment. It also imposes considerable constraints on both communications and act
Slide 17: General Queries (3)
General Queries (3) • In addition to your pipeline page on the website can you add a website page with the milestones expected for each quarter going forwards so Investors have some visibility regarding what we may expect updates on? Progress updates on pipeline drugs? Just basic info like trial dat
Slide 18: General Queries (4)
General Queries (4) • What have the Board achieved over the past 2 years other than delays to all projects? - In the past two years, we have completed the close out procedures and all regulatory required activities around the VAL201 clinical trial. We have verified, analysed and released the data fr
Slide 19: General Queries (5)
General Queries (5) • What have Cenkos done over the past 12 months to earn their fees? Why should we accept a further 6% dilution if they cash in their warrants? - The Cenkos team have been central to our progress over the past 12 months, providing face to face time of their extensive Corporate Fin
Slide 20: General Queries (5)
General Queries (5) • Can you seek any external support/ promotion. Perhaps considering engaging a sponsor or patron or spokesperson with a specific condition that the pipeline drug is trying to cure/improve? This could also highlight the work of Valirx, update on the drugs journey on an ongoing bas
Slide 21: Legacy Assets and Licenses
Legacy Assets and Licenses • Please could you provide an update on the Mystic licencing agreement which was announced on 28th July, 2017? Is the work progressing? Have any royalties been paid? What will happen when the licence expires next month? Did the previous management team obtain any benefit w
Slide 22: VAL201 (1)
VAL201 (1) • You decided to support a stateside start up SPV to take 201 forwards. Was this the only option? How is this business going to be structured? Is it going to be listed? What will the ownership structure of this business look like? • Can you confirm how much TheoremRx are raising? Can you
Slide 23: VAL201 (2)
VAL201 (2) • We understand that despite the service agreement being signed in November 2021 the 10k per month payment has not been received. Are they likely to pay it? Why did you agree to do all the support work to date Free of Charge? - We have never stated the amount of payment per month to be re
Slide 24: VAL201 (3)
VAL201 (3) • We appreciate that Due Diligence takes time, but you are granting yet a further extension, is there a point where you will have to say enough is enough and go back to square one and seek a new partner for 201. Will there be a point where the exclusivity period you granted to TRx will be
Slide 25: VAL301
VAL301 • Is it time now to move this from the Japanese company and either look for a with a new partner to advance this or shelve the asset if can’t be advanced for what ever reason? We accept that not all pipeline assets will succeed are we flogging a dead horse here or do you genuinely see a posit
Slide 26: VAL401
VAL401 • What is going on with VAL401. Is there any progress on this drug? - As announced in our previous updates, VAL401 is undergoing an extensive business development initiative to identify potential partners in either oncology or supportive care for oncology - This process is progressing well, a
Slide 27: BC201 for sepsis
BC201 for sepsis • Will this move to Phase 1 or at least to point of being fully optimised? What timeline do you have to get to the fully optimisation point? How active are the partners on this? - BC201 is an early stage programme being led by our partner OncoLytika - The ValiRx involvement is limit
Slide 28: New Assets
New Assets • The Triple Negative Breast Cancer evaluation programme we await the update on, but can you also add to the pipeline the other assets that are also under evaluation? • Will you be able to add more new pipeline assets to advance? It would be good to see at least 4 new pipeline assets adde